TICKERNERD
Menu
NXTCNXTCHealthcare · Biotechnology

NXTC Stock Forecast: NextCure, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$7.00
−4.24% on the day

The 1 Wall Street analysts covering NextCure, Inc. hold a median 12-month price target of $20 — +185.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 11 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$32.0M
Ticker Nerd rank
80 / 100
Median analyst target
$20
Analysts covering
1
Free cash flow−$9.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.7%
1M
+4.0%
YTD
−50.7%
1Y
+28.7%
From 52W high
−50.9%
From 52W low
+337.5%
$2
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NXTC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NextCure, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Size
85
Accruals
84
Revisions
84
Momentum
73
Issuance
57
Quality
26
Value
25
Volatility
20

Growth (86): Sales and profits are climbing, and climbing faster than before.

Volatility (20): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NXTC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NXTC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Oct 25Jan 26Apr 26Jul 26NXTCHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $20Median $20High $20

The green dot is the last close — the median target sits +185.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026LUCID CAPITAL MARKETSInitiatesBuy$25
7 Nov 2025Ladenburg ThalmannUpgradeBuy—
15 July 2025Piper SandlerMaintainsOverweight—
1 July 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Nov 2024HC Wainwright & Co.MaintainsBuy—
2 Aug 2024NeedhamReiteratesBuy—
3 June 2024HC Wainwright & Co.ReiteratesBuy—
31 May 2024HC Wainwright & Co.ReiteratesBuy—
3 May 2024HC Wainwright & Co.ReiteratesBuy—
3 May 2024NeedhamReiteratesBuy—
22 Mar 2024HC Wainwright & Co.MaintainsBuy—
20 Mar 2024NeedhamMaintainsBuy—
14 Dec 2023NeedhamMaintainsBuy—
8 Aug 2023HC Wainwright & Co.InitiatesBuy—
4 Aug 2023NeedhamReiteratesBuy—
5 May 2023NeedhamReiteratesBuy—
3 Mar 2023NeedhamReiteratesBuy—
4 Nov 2022Ladenburg ThalmannDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NXTC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NXTC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, NextCure, Inc. returned +28.7% against +17.5% for the S&P 500, dividends included.

NXTC vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250Oct 25Jan 26Apr 26Jul 26NXTCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NXTC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

NextCure, Inc. (NXTC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 79% of US stocks

Price / sales
—
Price / book
2.3×

Cheaper than 38% of US stocks

EV / EBITDA
−0.4×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−204.6%

Higher than 7% of US stocks

Return on assets
−69.0%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NextCure, Inc. (NXTC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NextCure, Inc. has a market value of $32.0M and an enterprise value of $16.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$37.0M.

  • Shares outstanding: 4.1M.

  • Trailing P/E: −0.4×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • NextCure, Inc. employs 40 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

NXTC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NXTCNextCure, Inc.$32.0M
80
CNTXContext Therapeutics, Inc.$32.2M
—
KYNBKyntra Bio, Inc.$32.3M
—
ALGSAligos Therapeutics, Inc.$32.3M
—
BYSIBeyondSpring, Inc.$31.4M
—
BCTXBriaCell Therapeutics Corp.$31.3M
—
LGVNLongeveron, Inc.$32.9M
—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NextCure, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NXTC news & analysis

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

PRNewsWire · 10 Aug 2026positive

Avere Therapeutics announced a $500 million private placement from leading healthcare investors, in addition to a previously announced $320 million concurrent private investment. The combined proceeds are expected to fully fund Avere's operating plan into 2029 and support development of its lead program, AVR-001, a once-weekly oral IL-23 receptor antagonist.

Why it matters — This financing strengthens the combined company's balance sheet to accelerate development of AVR-001, a development program relevant to NXTC watchers following the entity.

FAQ

Frequently asked questions about NXTC stock

What is the NXTC stock price forecast for 2026-2027?

The 1 Wall Street analysts covering NextCure, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NXTC stock a buy right now?

Of the 1 analysts covering NextCure, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NextCure, Inc. 80 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NXTC?

As at 11 Sept 2026, NextCure, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will NXTC stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +185.7% from the last close, and Ticker Nerd's factor model ranks NextCure, Inc. 80 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NXTC stock forecast for 2030?

No analyst covering NextCure, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has NXTC stock performed over the past year?

NextCure, Inc. returned +28.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NextCure, Inc. do?

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines for cancer and other immune-related diseases.

What is the latest news on NXTC?

The most recent item we track (PRNewsWire, 10 Aug 2026): "Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001". Avere Therapeutics announced a $500 million private placement from leading healthcare investors, in addition to a previously announced $320 million concurrent private investment. The combined proceeds are expected to fully fund Avere's operating plan into 2029 and support development of its lead program, AVR-001, a once-weekly oral IL-23 receptor antagonist.

Company

About NextCure, Inc.

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing immunomedicines for cancer and other immune-related diseases. The company’s work centers on identifying biological pathways, biomarkers, and immune-cell interactions within the tumor microenvironment to create therapies for patients whose cancers do not respond well to current treatments. Its current programs emphasize targeted approaches such as antibody-drug conjugates and other differentiated mechanisms of action designed to address difficult-to-treat tumors. NextCure also uses its FIND-IO discovery platform to help identify novel immune targets and support pipeline development. Headquartered in Beltsville, Maryland, NextCure plays a specialized role in the oncology and immunology markets by advancing experimental therapies intended to improve treatment options for patients with limited alternatives.

CEO Mr. Michael S. Richman MSBA · 40 employees · United States · https://www.nextcure.com